<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380691</url>
  </required_header>
  <id_info>
    <org_study_id>12613</org_study_id>
    <secondary_id>H9P-EW-LNCV</secondary_id>
    <nct_id>NCT01380691</nct_id>
  </id_info>
  <brief_title>A Study of LY2216684 in Healthy Subjects</brief_title>
  <official_title>A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction of LY2216684 With Alcohol in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684
      with Alcohol in Healthy Subjects. This study will run approximately for 34 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Power of Attention Composite Score</measure>
    <time_frame>Predose, up to 10 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Continuity of Attention Composite Score</measure>
    <time_frame>Predose, up to 10 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Postural Stability</measure>
    <time_frame>Predose, up to 10 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Self-Rated Alertness</measure>
    <time_frame>Predose, up to 10 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: maximum plasma concentration (Cmax) of LY2216684 and Alcohol</measure>
    <time_frame>Predose and up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: time to maximum plasma concentration (tmax) of LY2216684 and Alcohol</measure>
    <time_frame>Predose and up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: area under the concentration-time curve over a dosing interval (AUCt) of LY2216684</measure>
    <time_frame>Predose and up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: area under the concentration-time curve from time zero to the last time point with a measurable concentration [AUC(0-tlast)] of Alcohol</measure>
    <time_frame>Predose and up to 12 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Working Memory</measure>
    <time_frame>Predose, up to 10 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Episodic Memory</measure>
    <time_frame>Predose, up to 10 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Speed of Retrieval of Information from Memory</measure>
    <time_frame>Predose, up to 10 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-Ratings of Calmness and Contentment</measure>
    <time_frame>Predose, up to 10 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 18 mg LY2216684 administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of alcohol containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally, one time. There will be a 7 day washout period between periods 1 and 2. Period 2: LY2216684 Placebo administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of alcohol containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally, one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: LY2216684 Placebo administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of alcohol containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally, one time. There will be a 7 day washout period between periods 1 and 2. Period 2: 18 mg LY2216684 administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of alcohol containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally, one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 18 mg LY2216684 administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of alcohol containing beverage, to be taken orally, one time. There will be a 7 day washout period between periods 1 and 2. Period 2: LY2216684 Placebo administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of alcohol containing beverage, to be taken orally, one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:LY2216684 Placebo administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of alcohol containing beverage, to be taken orally, one time. There will be a 7 day washout period between periods 1 and 2. Period 2: 18 mg LY2216684 administered orally once daily for 8 days. On day 6, participant will be administered 2 cups of Alcohol placebo containing beverage, to be taken orally one time. On day 8, participant will be administered 2 cups of alcohol containing beverage, to be taken orally, one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2216684</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2216684 Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcohol Placebo containing beverage</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcohol containing beverage</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  Male subjects: Agree to use a reliable method of birth control during the study and
             for 1 month following the last dose of study drug.

          -  Female subjects: Are women of child-bearing potential who test negative for pregnancy
             at the time of enrollment, have used a reliable method of birth control for 6 weeks
             prior to administration of study drug, and agree to use a reliable method of birth
             control during the study and for 1 month following the last dose of study drug
             (hormonal methods of contraception, including oral and implantable contraceptives, are
             not allowed in this study); or Women who are not of child-bearing potential due to
             surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or
             are in menopause (at least 1 year without menses or 6 months without menses and a
             follicle stimulating hormone [FSH] &gt;40 mIU/mL).

          -  Male and female subjects: Examples of reliable methods of birth control include:
             Double-barrier methods (eg, condom and spermicide) alone or in combination with
             vasectomy, vasectomized partners, and abstinence.

          -  Have a body weight &gt;50 kg

          -  Have clinical laboratory test results within normal reference range for the population
             or investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator

          -  Have venous access sufficient to allow for blood sampling

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  Have given written informed consent approved by Lilly and the institutional review
             board (IRB) governing the site

          -  Have normal blood pressure and pulse rate (sitting position) as determined by the
             investigator

        Exclusion Criteria:

          -  Are currently enrolled in, have completed or discontinued within the last 30 days
             from, a clinical trial involving an investigational product other than the study drug
             used in this study; or are concurrently enrolled in any other type of medical research
             judged not to be scientifically or medically compatible with this study

          -  Have known allergies to LY2216684, related compounds or any components of the
             formulation

          -  Are persons who have previously received the investigational product in this study or
             have completed or withdrawn from this study or any other study investigating LY2216684
             within 6 months prior to Screening

          -  Have an abnormality in the 12-lead Electrocardiogram (ECG) that, in the opinion of the
             investigator, increases the risks associated with participating in the study.

          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Have a history or show evidence of significant active neuropsychiatric disease or have
             a history of suicide attempt or ideation

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Subjects with a past history of alcohol dependence/abuse

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV
             antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Are women with a positive pregnancy test or women who are lactating

          -  Intend to use over-the-counter or prescription medication within 14 days prior to
             dosing or during the study unless deemed acceptable by the investigator and Sponsor's
             medical monitor, except for influenza vaccinations

          -  Have donated blood of more than 500 mL within the last month

          -  Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling
             to stop alcohol consumption 48 hours prior to each study period and while resident at
             the Clinical Research Unit(CRU) (except as required per this protocol); (1 unit = 12
             oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)

          -  Consume 5 or more cups of coffee (or other beverages of comparable caffeine content)
             per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine
             restrictions

          -  Have consumed grapefruit or grapefruit-containing products 7 days prior to enrollment
             or unwilling to abstain during the study

          -  Have a documented or suspected history of glaucoma

          -  Subjects with known or suspected alcohol dehydrogenase deficiency

          -  Subjects who do not drink alcohol and/or are not willing to drink 4 units of alcohol
             over a 15-minute period

          -  Subjects determined to be unsuitable by the investigator for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>September 16, 2011</last_update_submitted>
  <last_update_submitted_qc>September 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Phenylethyl Alcohol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 17, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

